ASRS 2023: insights on fluid control with faricimab compared to aflibercept in recent studies with Aleksandra Rachiskaya, MD

Aleksandra Rachiskaya, MD, detailed her 2023 ASRS presentation, focused on time to fluid control with faricimab arms complete compared to aflibercept in recent studies.

Video Transcript

Editor's note - This transcript has been edited for clarity.

Aleksandra Rachiskaya, MD:

So I think when we, when we think about "how does this apply to me? You know, how am I going to take this data, where we see this shorter time to fluid control with faricimab arms complete compared to aflibercept? And how does it apply to my practice?" I think it's quite impactful, bcause we we want to control patients better....We're looking at further analysis to see how this translates to visual acuity outcomes as well. But we want to control the fluid because a lot of our treatment decisions are based on presence or absence of fluid.

So with faricimab drying patients faster, it will impact how we take care of patients in our clinics. So, I think one of the questions that we're looking at as pertaining to this particular topic is, you know, is looking at the visual acuity also. You know, does this faster drying translates into into visual acuity benefits? I'm curious to see how that data comes out and and share it with everybody.